Enrollment is complete in a phase 2 clinical trial of NCX 470, Nicox’s second-generation nitric oxide-donating bimatoprost analog, for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension, according to a press release.
The multicenter, double-masked, 28-day, parallel group, dose response study is comparing NCX 470 ophthalmic solution with latanoprost ophthalmic solution 0.005%. Its primary endpoint is a mean reduction in diurnal IOP after 28 days, with a main objective of identifying an appropriate dose of NCX 470 to advance to phase 3 studies, the release
Uncategorized